Security
PTN · PALATIN TECHNOLOGIES INC
PTNNYSE_AMERICANCommon stockHistorical · closed May 27, 2026CIK 911216Updated Sep 29, 2026
PTN price & chart
This listing closed May 27, 2026. Live provider charts are shown only for current listings.
Current security: PTN
About the company
We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
In the news
No coverage from other publishers is available.
Recent filings
10-K filing
SCHEDULE 13G/A filing
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
DEF 14A filing
CERT filing
Show 5 more recent filings
8-A12B filing
25 filing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Regulation FD Disclosure
Items 3.01, 7.01, 9.01
SCHEDULE 13G/A - filed by Logos Global Management LP regarding PALATIN TECHNOLOGIES INC
SCHEDULE 13G/A - filed by Point72 Asset Management, L.P. regarding PALATIN TECHNOLOGIES INC
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 3,266,954Source | 10,742,266Source | 17,939,440Source | 36,070,794Source |
| Property, Plant and Equipment, NetUSD | 129,444Source | 388,361Source | 684,910Source | 539,314Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,564,265Source | 9,527,396Source | 10,982,472Source | 29,939,154Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 0Source | 2,915,760Source | 1,780,020Source |
| Inventory, NetUSD | — | 0Source | 526,000Source | 944,471Source |
| Assets, CurrentUSD | 2,919,428Source | 9,769,668Source | 16,321,513Source | 34,596,099Source |
| Prepaid Expense and Other Assets, CurrentUSD | 325,695Source | 242,272Source | 1,897,281Source | 1,932,454Source |
| Operating Lease, Right-of-Use AssetUSD | 161,166Source | 527,321Source | 876,101Source | 878,465Source |
| Other Assets, NoncurrentUSD | 56,916Source | 56,916Source | 56,916Source | 56,916Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 8,043,999Source | 10,853,763Source | 17,805,367Source | 19,802,919Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | — | — | 40Source | 40Source |
| Common Stock, Value, IssuedUSD | 9,296Source | 179,266Source | 116,567Source | 92,709Source |
| Additional Paid in CapitalUSD | 454,287,484Source | 441,475,747Source | 415,553,049Source | 404,168,822Source |
| Retained Earnings (Accumulated Deficit)USD | -459,073,899Source | -441,766,550Source | -415,535,583Source | -387,993,696Source |
| Stockholders' Equity Attributable to ParentUSD | -4,777,045Source | -111,497Source | 134,073Source | 16,267,875Source |
| Liabilities and EquityUSD | 3,266,954Source | 10,742,266Source | 17,939,440Source | 36,070,794Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 8,010,030Source | 9,657,681Source | 15,131,830Source | 16,259,864Source |
| Operating Lease, Liability, CurrentUSD | 129,812Source | 380,542Source | 354,052Source | 371,124Source |
| Accounts Payable, CurrentUSD | 6,998,806Source | 4,101,929Source | 4,303,527Source | 3,157,617Source |
| Operating Lease, Liability, NoncurrentUSD | 33,969Source | 163,782Source | 544,323Source | 529,398Source |
| Other Liabilities, NoncurrentUSD | — | 0Source | 2,083,200Source | 2,861,250Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 881,412Source | 4,185,046Source | 6,511,059Source | 6,875,216Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -17,307,349Source | — | -27,541,887Source | — |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | 126,668Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,382,281Source | 1,872,698Source | 1,410,917Source | 2,505,538Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 0Source | 2,915,760Source | -1,135,740Source | 199,577Source |
| Increase (Decrease) in InventoriesUSD | 0Source | -1,154,355Source | 418,471Source | -217,529Source |
| Increase (Decrease) in Accounts PayableUSD | 2,896,877Source | -201,598Source | 1,109,541Source | 2,572,657Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -21,306,637Source | -31,461,441Source | -28,419,001Source | 18,358Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 3,130,000Source | 12,450,364Source | -3,426,817Source | -261,374Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 42,526Source | 433,927Source | 261,374Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 99,482Source | 56,401Source | 146,062Source | 221,311Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 11,213,506Source | 20,548,891Source | 9,896,246Source | -29,922,749Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,564,265Source | 9,527,396Source | 7,989,582Source | — |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 15,025Source | 17,114Source | 20,013Source | 29,682Source |
| Additional Financial Items | ||||
| Derivative, Gain (Loss) on Derivative, NetUSD | — | -6,962,562Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -50Source | — | -429,971Source | 389,868Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -50Source | 59,753Source | 429,971Source | — |
| Gain (Loss) on Disposition of AssetsUSD | 3,130,000Source | 7,781,844Source | — | — |
| Gain (Loss) on Disposition of BusinessUSD | — | 7,781,844Source | — | — |
| Gain (Loss) on Disposition of Other AssetsUSD | 3,130,000Source | -7,781,844Source | — | — |
| General and Administrative ExpenseUSD | — | — | — | 16,511,942Source |
| Income Tax Expense (Benefit)USD | — | 0Source | 4,674,999Source | — |
| Net Income (Loss) Attributable to ParentUSD | -17,307,349Source | -29,736,113Source | -27,541,887Source | -36,198,299Source |
| Nonoperating Income (Expense)USD | — | — | — | 390,149Source |
| Operating ExpensesUSD | 17,459,939Source | 26,986,211Source | 37,312,561Source | 38,056,905Source |
| Operating Lease, ExpenseUSD | 610Source | 5,507Source | 10,975Source | 8,812Source |
| Other Nonoperating Income (Expense)USD | 152,590Source | -7,239,992Source | 241,997Source | — |
| Proceeds from Issuance of Common StockUSD | 7,960,765Source | 14,666,042Source | 10,143,152Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 0Source | 16,132Source |
| Stock or Unit Option Plan ExpenseUSD | 702,789Source | 873,633Source | 794,735Source | 1,563,686Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 0Source | 4,490,090Source | 4,853,678Source | 1,468,457Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 7,809,345Source | 12,270,046Source | 15,290,836Source | — |
| Operating Income (Loss)USD | -17,459,939Source | -22,496,121Source | -32,458,883Source | -36,588,448Source |
| Other Nonoperating Income (Expense)USD | 152,590Source | -7,239,992Source | 241,997Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -32,216,886Source | — |
| Income Tax Expense (Benefit)USD | — | 0Source | 4,674,999Source | — |
| Net Income (Loss) Attributable to ParentUSD | -17,307,349Source | -29,736,113Source | -27,541,887Source | -36,198,299Source |
| Earnings Per Share, BasicUSD per share | — | -2.02Source | — | — |
| Earnings Per Share, DilutedUSD per share | -32.15Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | 14,697,096Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 538,348Source | — | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 9,224,056Source | 9,224,056Source | 9,109,117Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 258,917Source | 339,075Source | 288,331Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -50Source | — | -429,971Source | 389,868Source |
| General and Administrative ExpenseUSD | — | — | — | 16,511,942Source |
| Interest ExpenseUSD | 15,025Source | 17,114Source | 20,013Source | 29,682Source |
| Investment Income, NetUSD | 167,665Source | 376,843Source | 691,981Source | 29,963Source |
| Nonoperating Income (Expense)USD | — | — | — | 390,149Source |
| Operating ExpensesUSD | 17,459,939Source | 26,986,211Source | 37,312,561Source | 38,056,905Source |
| Operating Lease, ExpenseUSD | 610Source | 5,507Source | 10,975Source | 8,812Source |
| Other ExpensesUSD | 0Source | 696,912Source | — | — |
| Research and Development ExpenseUSD | 14,898,494Source | 22,400,372Source | 22,630,577Source | 21,327,434Source |
Offerings
Registration 333-290641
- Gross proceeds
- 15799800.0
- Net proceeds
- 14693814.0
- Deal price
- 6.5
- Shares
- 2430738
- Offering price
- $6.50
- Ticker
- PTN
Registration 333-286280
- Gross proceeds
- 15799800.0
- Net proceeds
- 14693814.0
- Deal price
- 6.5
- Shares
- 2430738
- Offering price
- $6.50
- Ticker
- PTN
Filing attachments
ex99-1.htm · 8-K · 2026-05-18
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Palatin to Begin Trading on Nasdaq Stock Exchange PRINCETON, NJ - May 18, 2026 /PRNewswire/ - Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from …
Read attachment ↗ptn_ex991.htm · 8-K · 2025-11-12
EX-99.1 3 ptn_ex991.htm PRESS RELEASE ptn_ex991.htm EXHIBIT 99.1 Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters’ Over-Allotment Option Trading of Palatin’s common shares resumed trading on NYSE today, November 12, 2025, under the symbol “PTN” PRINCETON, NJ - November 12, 2025 /PRNewswire/ - Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-i…
Read attachment ↗ptn_ex41.htm · 8-K · 2025-11-06
EX-4.1 3 ptn_ex41.htm FORM OF PRE-FUNDED WARRANT ptn_ex41.htm EXHIBIT 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [ ], 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial E…
Read attachment ↗ptn_ex42.htm · 8-K · 2025-11-06
EX-4.2 4 ptn_ex42.htm FORM OF SERIES J WARRANT ptn_ex42.htm EXHIBIT 4.2 SERIES J COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [ ], 2025 Initial Exercise Date: [ ], 2025 THIS SERIES J COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a…
Read attachment ↗ptn_ex43.htm · 8-K · 2025-11-06
EX-4.3 5 ptn_ex43.htm FORM OF SERIES K WARRANT ptn_ex43.htm EXHIBIT 4.3 SERIES K COMMON STOCK PURCHASE WARRANT PALATIN TECHNOLOGIES, INC. Warrant Shares: [•] Issue Date: [ ], 2025 Initial Exercise Date: [ ], 2025 THIS SERIES K COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, a…
Read attachment ↗ptn_ex991.htm · 8-K · 2025-11-06
EX-99.1 6 ptn_ex991.htm PRESS RELEASE ptn_ex991.htm EXHIBIT 99.1 Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering $15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milestone related warrants Regains compliance with NYSE American exchange listing standard - trading of Palatin’s common shares will resume on November 12, 2025, under the symbol “PTN” PRINCETON, N.J., November 6, 2025 /PRNewswire/ -- Palatin Techno…
Read attachment ↗